Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Della F Makower"'
Autor:
Gayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M Kuderer, David M Aboulafia, Jared D Acoba, Joy Awosika, Ziad Bakouny, Nicole B Balmaceda, Ting Bao, Babar Bashir, Stephanie Berg, Mehmet A Bilen, Poorva Bindal, Sibel Blau, Brianne E Bodin, Hala T Borno, Cecilia Castellano, Horyun Choi, John Deeken, Aakash Desai, Natasha Edwin, Lawrence E Feldman, Daniel B Flora, Christopher R Friese, Matthew D Galsky, Cyndi J Gonzalez, Petros Grivas, Shilpa Gupta, Marcy Haynam, Hannah Heilman, Dawn L Hershman, Clara Hwang, Chinmay Jani, Sachin R Jhawar, Monika Joshi, Virginia Kaklamani, Elizabeth J Klein, Natalie Knox, Vadim S Koshkin, Amit A Kulkarni, Daniel H Kwon, Chris Labaki, Philip E Lammers, Kate I Lathrop, Mark A Lewis, Xuanyi Li, Gilbert de Lima Lopes, Gary H Lyman, Della F Makower, Abdul-Hai Mansoor, Merry-Jennifer Markham, Sandeep H Mashru, Rana R McKay, Ian Messing, Vasil Mico, Rajani Nadkarni, Swathi Namburi, Ryan H Nguyen, Taylor Kristian Nonato, Tracey Lynn O'Connor, Orestis A Panagiotou, Kyu Park, Jaymin M Patel, Kanishka GopikaBimal Patel, Jeffrey Peppercorn, Hyma Polimera, Matthew Puc, Yuan James Rao, Pedram Razavi, Sonya A Reid, Jonathan W Riess, Donna R Rivera, Mark Robson, Suzanne J Rose, Atlantis D Russ, Lidia Schapira, Pankil K Shah, M Kelly Shanahan, Lauren C Shapiro, Melissa Smits, Daniel G Stover, Mitrianna Streckfuss, Lisa Tachiki, Michael A Thompson, Sara M Tolaney, Lisa B Weissmann, Grace Wilson, Michael T Wotman, Elizabeth M Wulff-Burchfield, Sanjay Mishra, Benjamin French, Jeremy L Warner, Maryam B Lustberg, Melissa K Accordino, Dimpy P Shah, On behalf of the COVID-19 and Cancer Consortium
Publikováno v:
eLife, Vol 12 (2023)
Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry
Externí odkaz:
https://doaj.org/article/21b528e377ff490f938d7fabb4ca5424
Autor:
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley, Chirag R Jani, Craig Mescher, Shabana J Dewani, Ursa Brown-Glaberman, Lisa E Flaum, Erica L Mayer, William M Sikov, Eve T Rodler, Angela M DeMichele, Joseph A Sparano, Antonio C Wolff, Kathy D Miller, Lynne I Wagner
Publikováno v:
Cancer Research. 82:P4-10
Background: Understanding health-related quality of life (HRQOL), including side effects, is critical to guide supportive care during chemotherapy. The EA1131 trial demonstrated that Platinum (Plat) was unlikely to improve outcomes compared to capeci
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Lymphovascular invasion (LVI) and Black race are associated with poorer prognosis in early breast cancer (EBC). We evaluated the association between LVI and race, and whether LVI adds prognostic benefit to the 21-gene recurrence score (RS) in EBC. Wo
Autor:
Karen L. Smith, Bernard Tawfik, William Fraser Symmans, Kathy D. Miller, Erica L. Mayer, Ingrid A. Mayer, Margaret Block, Angela DeMichele, Shabana Jaynul Dewani, Amye J. Tevaarwerk, Carlos L. Arteaga, Lisa Flaum, Della F. Makower, Craig Mescher, Chirag Jani, Joseph A. Sparano, Lynne I. Wagner, Fengmin Zhao, William M. Sikov, Eve T. Rodler, Ben Ho Park, Kimberly A. Morley, Brian L. Burnette, Antonio C. Wolff, Sofia F. Garcia
Publikováno v:
Journal of Clinical Oncology. 39:3522-3524
Publikováno v:
Cancer Research. 81:PS6-20
Background: The Oncotype DX 21-gene expression assay (ODX) is prognostic for recurrence and predictive of chemotherapy benefit in early estrogen receptor-positive (ER+) HER2-negative (HER2-) breast cancer (BCA). Invasive ductal carcinoma (IDC) compri
Autor:
Eleni Andreopoulou, Della F. Makower, Anupama Goel, Andrea Califano, Dawn L. Hershman, Paula Klein, Naomi Sender, Tessa Cigler, Shing Lee, Lauren Franks, Prabhjot S. Mundi, Magdalena Galazyn, Kevin Kalinsky, Joseph A. Sparano, Lauren Esther Blumberg, Jose Silva, Amy Tiersten, Dow-Chung Chi, Kristina Hosi, Katherine D. Crew
Publikováno v:
Cancer Research. 80:P1-19
Background: Preclinical and clinical studies suggest that trastuzumab resistance in HER2+ BC is mediated by cross-activation of alternative signaling pathways. Computational analysis and pooled whole-genome RNAi screens in HER2 transformed BC cell li
Publikováno v:
Cancer Research. 80:P3-08
Background: LVI and black race are associated with poorer prognosis in early breast cancer (BCA). The Oncotype DX 21-gene Recurrence Score (RS) is both prognostic for recurrence and predictive of chemotherapy benefit in estrogen-receptor positive (ER
Autor:
Julia R. Trosman, Swati Kulkarni, Rachel Podrazik Baer, Lawrence Eric Feldman, Mary Pasquinelli, Sheetal Mehta Kircher, Al Bowen Benson, William John Gradishar, Bruce Rapkin, Della F. Makower, Claudia Beth Perez, Stephanie Boecher, Arliene Ravelo Mangalindan, Elaine Yu, Christine B. Weldon
Publikováno v:
Journal of Clinical Oncology. 40:344-344
1542 Background: The 4R Oncology model was proposed within the NCI ASCO Teams Project as an approach to facilitate patient-facing care planning, team-based delivery and patient self-management. 4R (Right Info/Care/Patient/Time) enables care teams and
Autor:
Della F. Makower, Editha A. Krueger, Al B. Benson, Lidia Schapira, Jennifer Van Horn, Alyssa D. Throckmorton, Claudia B. Perez, Cathleen M. Schaeffer, Su-Ying Liang, Swati Kulkarni, Elaine W. Yu, Kent Hoskins, Julia R. Trosman, Christine B. Weldon, William J. Gradishar, Shelly S. Lo, Arliene Ravelo, Christopher Gallagher, Bruce D. Rapkin
Publikováno v:
JCO oncology practice. 17(8)
PURPOSE: Optimal cancer care requires patient self-management and coordinated timing and sequence of interdependent care. These are challenging, especially in safety-net settings treating underserved populations. We evaluated the 4R Oncology model (4
Autor:
Carlos L. Arteaga, Margaret Block, Shabana Jaynul Dewani, Lisa Flaum, William Fraser Symmans, Angela DeMichele, Chirag Jani, Karen L. Smith, Amye J. Tevaarwerk, Erica L. Mayer, Fengmin Zhao, Bernard Tawfik, Eve T. Rodler, Della F. Makower, Lynne I. Wagner, Kathy D. Miller, Joseph A. Sparano, Craig Mescher, Kimberly A. Morley, Sofia F. Garcia, William M. Sikov, Ben Ho Park, Ingrid A. Mayer, Brian L. Burnette, Antonio C. Wolff
Publikováno v:
J Clin Oncol
PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c662aa16b723441992e414909d49913c
https://europepmc.org/articles/PMC8577688/
https://europepmc.org/articles/PMC8577688/